PROCEPT BioRobotics (PRCT)
(Delayed Data from NSDQ)
$57.38 USD
-4.62 (-7.45%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $57.45 +0.07 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
PRCT 57.38 -4.62(-7.45%)
Will PRCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRCT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PRCT
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Tops Revenue Estimates
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
PRCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
Other News for PRCT
Strong Buy Rating for PROCEPT BioRobotics Amidst Surging Q2 Performance and Market Adoption
PROCEPT BioRobotics Corp (PRCT) Q2 2024 Earnings Call Transcript Highlights: Record Revenue ...
PROCEPT BioRobotics (PRCT) Receives a Buy from Truist Financial
Strong Growth and Robust Performance Justify Buy Rating for PROCEPT BioRobotics
Piper Sandler Issues a Buy Rating on PROCEPT BioRobotics (PRCT)